Neurogastrx rakes in $60m Series B

Neurogastrx, a developer of treatments for gastrointestinal disorders, has secured $60 million in Series B funding.

To read this article, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to read this article and more for free.

Share this